SCHEMBL12224752

SCHEMBL12224752

Cc1nc2c(N3CCN(C)CC3)nc3ccc(C(F)(F)F)cc3n2n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 9/20 0.51
KDM4E B2RXH2 2/20 0.51
HSD17B10 Q99714 2/20 0.51
TP53 P04637 2/20 0.51
HTR3E A5X5Y0 1/20 0.51
HTR3B O95264 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
HTR1A P08908 1/20 0.51
CYP2D6 P10635 1/20 0.51
TSHR P16473 1/20 0.51
NFKB1 P19838 1/20 0.51
HTR1D P28221 1/20 0.51
HTR2C P28335 1/20 0.51
CYP2C19 P33261 1/20 0.51
THPO P40225 1/20 0.51
HTR3A P46098 1/20 0.51
HTR3D Q70Z44 1/20 0.51
HTR3C Q8WXA8 1/20 0.51
POLB P06746 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12224756 0.88 HTR2C (0.50) HRH4KDM4EHSD17B10TP53HTR3E
SCHEMBL405499 0.82 HRH4 (0.54) HRH4KDM4ETP53HTR3EHTR3B
SCHEMBL406048 0.82 HRH4 (0.66) HRH4KDM4EHSD17B10TP53HTR3A
SCHEMBL12224810 0.82 HTR3E (0.51) HRH4KDM4EHSD17B10TP53HTR3E
SCHEMBL439563 0.82 POLB (0.67) HRH4KDM4EHSD17B10TP53HTR3E
SCHEMBL12224870 0.81 HRH4 (0.50) HRH4KDM4EHSD17B10TP53HTR3E
SCHEMBL12224758 0.81 POLB (0.42) HRH4HSD17B10TSHRPOLBHRH3
SCHEMBL12225221 0.80 HRH4 (0.54) HRH4KDM4ETP53HTR3EHTR3B
SCHEMBL2467900 0.80 HRH4 (0.51) HRH4KDM4ETP53HTR3EHTR3B
SCHEMBL440877 0.78 HRH4 (0.50) HRH4KDM4EHSD17B10TP53HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
WO-2011112731-A2 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-09-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 HRH4 1/4885KDM4E 1897/4885HSD17B10 3443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.